Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
Find a Broker »
- li>
- li>
- li>
- li>
- li>
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
998,904 | 911,183 | 949,309 | 939,114 | 1,010,445 |
Cost of Goods Sold (COGS) incl. D&A |
441,230 | 432,697 | 407,302 | 385,787 | 431,328 |
COGS excluding D&A |
332,761 | 326,768 | 297,813 | 280,781 | 314,924 |
Depreciation & Amortization Expense |
108,469 | 105,929 | 109,489 | 105,006 | 116,404 |
Gross Income |
557,674 | 478,486 | 542,007 | 553,327 | 579,117 |
SG&A Expense |
348,271 | 355,376 | 347,883 | 341,996 | 339,736 |
Research & Development |
83,667 | 84,811 | 84,816 | 88,598 | 90,201 |
Other SG&A |
264,604 | 270,565 | 263,067 | 253,398 | 249,535 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
47,541 | 24,732 | -14,133 | 25,018 | 55,883 |
Non Operating Income/Expense |
8,419 | 11,526 | -26,016 | 4,890 | -16,788 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | NA | 0 |
Interest Expense |
29,794 | 29,437 | 29,383 | 35,592 | 38,308 |
Gross Interest Expense |
29,794 | 29,437 | 29,383 | 35,592 | 38,308 |
Pretax Income |
141,173 | 80,903 | 153,373 | 156,375 | 128,402 |
Income Tax |
31,268 | 15,301 | 31,070 | 23,736 | 35,334 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
109,905 | 65,602 | 122,303 | 132,639 | 93,068 |
Minority Interest Expense |
-101 | -255 | -51 | 0 | 0 |
Net Income |
110,006 | 65,857 | 122,354 | 132,639 | 93,068 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | NA | 0 | 0 |
Net Income After Extraordinaries |
110,006 | 65,857 | 122,354 | 132,639 | 93,068 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
110,006 | 65,857 | 122,354 | 132,639 | 93,068 |
Operational EPS |
0.82 | 0.47 | 0.62 | 0.82 | 0.71 |
EPS (basic) |
0.64 | 0.38 | 0.69 | 0.74 | 0.52 |
EBITDA |
317,872 | 229,039 | 303,613 | 316,337 | 355,785 |
Depreciation & Amortization Expense |
108,469 | 105,929 | 109,489 | 105,006 | 116,404 |
Common Shares Outstanding |
174,612 | 177,258 | 181,307 | 183,113 | 185,595 |
Basic Shares Outstanding |
171,884 | 174,044 | 178,168 | 178,873 | 179,390 |
Diluted Shares Outstanding |
174,612 | 177,258 | 181,307 | 183,113 | 185,595 |
Diluted EPS after Extraordinary Items |
0.63 | 0.37 | 0.67 | 0.72 | 0.50 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.64 | 0.38 | 0.69 | 0.74 | 0.50 |
*Figures in thousands of U.S. Dollars except shares outstanding.